HomepageIMRN ⢠NASDAQ
add
Immuron Ltd - ADR
Vorige slotkoers
$Ā 0,81
Dag-range
$Ā 0,78 - $Ā 0,86
Jaar-range
$Ā 0,68 - $Ā 2,38
Beurswaarde
6,55Ā mln. USD
Gem. volume
24,18K
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiƫle informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (AUD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 2,09Ā mln. | 4,76% |
Bedrijfskosten | 2,31Ā mln. | -10,95% |
Netto inkomsten | -959,54K | 22,89% |
Netto winstmarge | -45,86 | 26,40% |
Winst per aandeel | ā | ā |
EBITDA | -974,15K | 22,56% |
Effectief belastingtarief | ā | ā |
Balans
Totale activa
Totale passiva
| (AUD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 10,00Ā mln. | 29,20% |
Totale activa | 15,14Ā mln. | 24,39% |
Totale passiva | 2,06Ā mln. | 12,62% |
Totaal aandelenvermogen | 13,08Ā mln. | ā |
Uitstaande aandelen | 326,65Ā mln. | ā |
Koers-boekwaardeverhouding | 20,25 | ā |
Rendement op activa | -16,29% | ā |
Rendement op kapitaal | -18,57% | ā |
Kasstroom
Nettomutatie in liquide middelen
| (AUD) | dec 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -959,54K | 22,89% |
Operationele kasstroom | -1,28Ā mln. | 36,06% |
Kasstroom uit beleggingen | 1,56Ā mln. | 5.670,97% |
Kasstroom uit financiering | 3,36Ā mln. | 16.129,60% |
Nettomutatie in liquide middelen | 3,58Ā mln. | 282,73% |
Vrije kasstroom | -621,04K | 21,85% |
Over
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Opgericht
1994
Hoofdvestiging
Website
Werknemers
7